Suptavumab

Suptavumab (also known as REGN2222) is a monoclonal antibody designed for the prevention of respiratory syncytial virus (RSV) infections. It was developed by Regeneron Pharmaceuticals but failed in Phase 3 clinical trials.

History

Suptavumab was developed by Regeneron Pharmaceuticals as a potential treatment for respiratory syncytial virus (RSV) infections. The drug was designed to bind to the RSV F protein, a fusion protein that allows the virus to enter host cells. By binding to this protein, suptavumab was intended to prevent the virus from infecting cells.

In 2017, Regeneron announced that suptavumab had failed in Phase 3 clinical trials. The drug did not significantly reduce the incidence of medically-attended RSV infections in infants, which was the primary endpoint of the trial.

Mechanism of Action

Suptavumab is a monoclonal antibody that targets the RSV F protein. This protein is essential for the virus's ability to infect host cells. By binding to the F protein, suptavumab was designed to prevent the virus from entering cells and causing an infection.

Clinical Trials

Suptavumab underwent Phase 3 clinical trials to test its efficacy in preventing RSV infections in infants. However, the drug did not meet its primary endpoint, which was a reduction in the incidence of medically-attended RSV infections.

Future Development

Following the failure of suptavumab in clinical trials, Regeneron has not announced any plans to continue its development.

See Also

• Monoclonal antibodies
• Respiratory syncytial virus
• Regeneron Pharmaceuticals

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia